Angiodynamics Financial Results
AngioDynamics reported fiscal first quarter 2027 net sales of $80.9 million, representing 6.9% year-over-year growth driven by its Med Tech segment. The company achieved a GAAP gross margin of 59.4% and an adjusted EBITDA of $5.0 million. Additionally, the company announced that Eric Honroth will succeed Jim Clemmer as President and CEO effective November 2, 2026.
- Term
- Q1 2027
“Our first quarter results reflect the continued, consistent execution we’ve built into this business. Med Tech again led our growth, highlighted by Auryon’s 21st consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform.”
Jim Clemmer, President and Chief Executive Officer
“As I shared previously, after ten years leading this company, I have decided to retire, and the Board has completed a comprehensive search for my successor. I’m pleased to share that Eric Honroth will become our next President and Chief Executive Officer.”
Jim Clemmer, President and Chief Executive Officer